Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic

Journal of Human Hypertension

Volumn 30, Issue 2, 2016, Pages 83-89

  Hameed, M A ^a   Tebbit, L ^a   Jacques, N ^a   Thomas, M ^a   Dasgupta, I ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HUMAN CELL; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; RESISTANT HYPERTENSION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DIRECTLY OBSERVED THERAPY; DRUG EFFECTS; FOLLOW UP; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED KINGDOM;

EID: 84953352503     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.38     Document Type: Article

References (48)

1. Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369(5): 448-457.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357.
3. National Institute for Health and Clinical Excellence Hypertension: Clinical Management of Primary Hypertension in Adults. National Institute for Health and Clinical Excellence: London, UK, 2011.
4. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57(5): 898-902.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57(6): 1076-1080.
6. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124(9): 1046-1058.
7. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123(4): e18-e209.
8. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125(13): 1635-1642.
9. Salles GF, Cardoso CL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Int Med 2008; 168(21): 2340-2346.
10. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens 2009; 11(7): 376-382.
11. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23(11): 2093-2100.
12. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23(11): 2101-2107.
13. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12(3): 243-249.
14. Romanelli RJ, Schiro TA, Jukes T, Wong KS, Ishisaka DY. Disparities in blood pressure control within a community-based provider network: an exploratory analysis. Ann Pharmacother 2011; 45(12): 1473-1482.
15. Di Matteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42(3): 200-209.
16. Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber LS et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO). J Hypertens 2015; 33(2): 412-420.
17. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-774.
18. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62(2): 218-225.
19. Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 2009; 27(8): 1540-1551.
20. Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, Di Carlo L et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS ONE 2013; 8(1): e53373.
21. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185(9): 487-489.
22. Kettani F, Dragomir A, Côté R, Roy L, Bérard A, Blais L et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40(1): 213-220.
23. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120(16): 1598-1605.
24. Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Int Med 2010; 25(6): 495-503.
25. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29(3): 610-618.
26. Esposti LD, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M et al. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinico Economics Outcomes Res 2011; 3: 47-54.
27. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940-2948.
28. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19(2): 335-341.
29. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 1999; 53(1): 37-38.
30. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of noninvasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens 1991; 9(2): 115-119.
31. Prisant LM, Carr AA, Bottini PB, Thompson WO, Rhoades RB. Repeatability of automated ambulatory blood pressure measurements. J Fam Pract 1992; 34(5): 569-574.
32. Staessen JA, Wang J, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358(9290): 1305-1315.
33. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393-1401.
34. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology, 7th edn, Churchill Livingstone: Edinburgh, 2012.
35. Bunker J, Callister W, Chang CL, Sever PS. How common is true resistant hypertension?. J Hum Hypertens 2011; 25(2): 137-140.
36. Fadl Elmula FEM, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62(3): 526-532.
37. Fadl Elmula FEM, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63(5): 991-999.
38. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100(11): 855-861.
39. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertension Res 2011; 34(1): 87-90.
40. Strauch B, Petrak O, Zelinka T, Rosa J, Somloova Z, Indra T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-2461.
41. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. The Am J Med 2012; 125(9): 882-887.
42. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Int Med 1990; 150(7): 1377-1378.
43. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 2014; 63(8): 834-835.
44. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22(10): 1849-1855.
45. Wetzels GEC, Nelemans PJ, Schouten JSAG, Dirksen CD, van der Weijden T, Stoffers HEJH et al. Electronic monitoring of adherence as a tool to improve blood pressure control∗: a randomized controlled trial. Am J Hypertens 2007; 20(2): 119-125.
46. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity htn-2 randomized, controlled trial. Circulation 2012; 126(25): 2976-2982.
47. Easthall C, Song F, Bhattacharya D. A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence. BMJ Open 2013; 3(8): e002749.
48. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A et al. A titrate-togoal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens 2011; 13(6): 404-412.